Zymeworks reported a decrease in Q4 revenue compared to the prior year as it transitions clinical activities to partners, while significantly reducing its full-year net loss. The company secured a $250 million royalty-backed note from Royalty Pharma to support its share repurchase program and strategic growth, extending its cash runway beyond 2028.

For Q3 2025, Zymeworks recognized total revenue of 27600000, driven by a $25.0 M milestone from Johnson & Johnson and $1.0 M in royalties, while reporting a net loss of 19600000 and diluted EPS of -0.26 as operating expenses remained elevated. Cash resources totaled 299400000 at quarter end. :contentReference[oaicite:0]{index=0}

In Q2 2025, Zymeworks delivered $48,726,000 in revenue, reflecting a significant increase from the prior year, with net income of $2,317,000 and diluted EPS of $0.03, supported by milestone payments and royalty revenue from collaborations while maintaining strong cash resources of $333,400,000 at quarter end. :contentReference[oaicite:0]{index=0}

Zymeworks reported a significant increase in revenue to $27.1 million for Q1 2025, up from $10.0 million in Q1 2024, primarily due to milestone payments from GSK and Daiichi Sankyo. The company also reduced its net loss to $22.6 million from $31.7 million in the prior year. Cash resources stood at $321.6 million, providing a projected cash runway into the second half of 2027.

For Q4 2024, Zymeworks generated revenue of 31000000 primarily due to initial royalty revenue and milestone payments from partnerships, while reporting a net loss of 23510000 and diluted EPS of -0.31 amid ongoing investment in pipeline development. Cash resources were 324200000 at quarter end. :contentReference[oaicite:0]{index=0}

Zymeworks reported a revenue of $16.0 million for the third quarter of 2024, a decrease from $16.5 million in the same period last year. The company's net loss for the quarter was $29.85 million, compared to $28.687 million in Q3 2023. Key highlights include the first patient dosed in a Phase 1 trial for ZW171, preclinical data presentations for ZW220 and ZW251, and the completion of an initial share repurchase program.

Zymeworks reported a net loss of $37.686 million for Q2 2024, an improvement from the $51.152 million loss in Q2 2023. Revenue from research and development collaborations was $19.243 million, significantly up from $7.002 million in the prior year. The company ended the quarter with $395.9 million in cash resources, projecting a cash runway into the second half of 2027.

Zymeworks reported a net loss of $31.7 million for the first quarter of 2024, an increase from $24.4 million in the same period last year. Revenue decreased to $10.0 million from $35.6 million in Q1 2023, primarily due to the transfer of responsibility for certain clinical trials to Jazz Pharmaceuticals. Despite the increased net loss, the company maintains a strong cash position of $420.5 million, projecting a cash runway into the second half of 2027.

Zymeworks Inc. reported a substantial increase in revenue for the fourth quarter and full year 2022, primarily due to a significant licensing agreement with Jazz Pharmaceuticals. The company achieved net income for the year, a significant improvement from a net loss in the previous year, and ended 2022 with a strong cash position, extending its cash runway through 2026.